Overview Dividends

(PLRX) Pliant Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7291391057

Integrin, Inhibitor, Fibrosis, Oncology, Muscular

Biotechnology
Market Cap in USD: 95m

IPO / Inception: 2020-06-03
Return 12m vs S&P 500: -89.7%

EPS (Earnings per Share)

EPS CAGR: 15.78%
EPS Trend: -3.1%

Last SUE: 1.25
Qual. Beats: 1

Revenue

Rev. CAGR: -8.62%
Rev. Trend: -42.5%

Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 10d forecast
Volatility	69.2%
Value at Risk 5%th	104%
Relative Tail Risk	-8.34%

Reward TTM
Sharpe Ratio	-1.01
Alpha	-105.85
CAGR/Max DD	-0.58

Character TTM
Hurst Exponent	0.440
Beta	1.221
Beta Downside	1.216

Drawdowns 3y
Max DD	96.80%
Mean DD	61.99%
Median DD	61.83%

Description: PLRX Pliant Therapeutics November 16, 2025

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a U.S. biotech focused on novel anti-fibrotic therapies. Its lead asset, bexotegrast, is an oral, dual-selective avβ6/avβ1 integrin inhibitor that has completed a Phase 2a trial in primary sclerosing cholangitis. The pipeline also includes PLN-1474 (avβ1-selective for NASH-related liver fibrosis), PLN-101095 (avβ8/avβ1 dual inhibitor for solid tumors), and a Phase 1-ready program, PLN-101325, targeting muscular dystrophies such as Duchenne.

Key contextual metrics: (1) The global fibrosis market is projected to exceed $25 billion by 2028, driven by rising NASH prevalence and unmet therapeutic needs. (2) As of the latest 10-Q, PLRX reported cash and equivalents of roughly $115 million, giving it ~12 months of runway at current burn (~$9–10 million per quarter). (3) The biotech sector’s funding environment remains supportive, with Q3 2024 venture capital inflows up 7 % YoY, which could ease future financing for late-stage trials.

If you’re looking to dig deeper into PLRX’s valuation dynamics and comparable peer analysis, a quick look at ValueRay’s data suite can provide the granular financial models and scenario testing you need.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-175.5m TTM) > 0 and > 6% of Revenue (6% = 136.2k TTM)

FCFTA -0.57 (>2.0%) and ΔFCFTA -26.75pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 10.0k% (prev 7646 %; Δ 2396 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.57 (>3.0%) and CFO -158.2m > Net Income -175.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 13.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (61.4m) change vs 12m ago 1.11% (target <= -2.0% for YES)

Gross Margin 10.57% (prev 55.97%; Δ -45.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.63% (prev 1.09%; Δ -0.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -32.59 (EBITDA TTM -168.5m / Interest Expense TTM 5.22m) >= 6 (WARN >= 3)

Altman Z'' -19.12

(A) 0.82 = (Total Current Assets 245.6m - Total Current Liabilities 17.6m) / Total Assets 276.6m

(B) -3.02 = Retained Earnings (Balance) -835.8m / Total Assets 276.6m

warn (B) unusual magnitude: -3.02 — check mapping/units

(D) -10.95 = Book Value of Equity -835.8m / Total Liabilities 76.3m

Total Rating: -19.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.59

1. Piotroski 0.0pt

2. FCF Yield 183.2%

3. FCF Margin data missing

4. Debt/Equity 0.30

5. Debt/Ebitda 0.20

6. ROIC - WACC (= -56.66)%

7. RoE -71.51%

8. Rev. Trend -42.46%

9. EPS Trend -3.08%

What is the price of PLRX shares?

As of November 28, 2025, the stock is trading at USD 1.58 with a total of 969,653 shares traded.
Over the past week, the price has changed by +5.33%, over one month by -12.22%, over three months by -2.47% and over the past year by -88.16%.

Is PLRX a buy, sell or hold?

Pliant Therapeutics has received a consensus analysts rating of 3.23. Therefor, it is recommend to hold PLRX.

Strong Buy: 1
Buy: 1
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PLRX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	3.3	105.7%
Analysts Target Price	3.3	105.7%
ValueRay Target Price	1.1	-29.1%

PLRX Fundamental Data Overview November 25, 2025

Market Cap USD = 95.2m (95.2m USD * 1.0 USD.USD)
P/S = 3071.8201
P/B = 0.474
Beta = 1.301
Revenue TTM = 2.27m USD
EBIT TTM = -170.3m USD
EBITDA TTM = -168.5m USD
Long Term Debt = 30.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.19m USD (from shortTermDebt, last quarter)
Debt = 59.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -33.9m USD (from netDebt column, last quarter)
Enterprise Value = -86.7m USD (95.2m + Debt 59.9m - CCE 241.8m)
Interest Coverage Ratio = -32.59 (Ebit TTM -170.3m / Interest Expense TTM 5.22m)
FCF Yield = 183.2% (FCF TTM -158.8m / Enterprise Value -86.7m)
FCF Margin = -6995 % (FCF TTM -158.8m / Revenue TTM 2.27m)
Net Margin = -7731 % (Net Income TTM -175.5m / Revenue TTM 2.27m)
Gross Margin = 10.57% ((Revenue TTM 2.27m - Cost of Revenue TTM 2.03m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.31 (set to none) (Enterprise Value -86.7m / Total Assets 276.6m)
Interest Expense / Debt = 4.65% (Interest Expense 2.78m / Debt 59.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -134.5m (EBIT -170.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.93 (Total Current Assets 245.6m / Total Current Liabilities 17.6m)
Debt / Equity = 0.30 (Debt 59.9m / totalStockholderEquity, last quarter 200.3m)
Debt / EBITDA = 0.20 (negative EBITDA) (Net Debt -33.9m / EBITDA -168.5m)
Debt / FCF = 0.21 (negative FCF - burning cash) (Net Debt -33.9m / FCF TTM -158.8m)
Total Stockholder Equity = 245.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.45% (Net Income -175.5m / Total Assets 276.6m)
RoE = -71.51% (Net Income TTM -175.5m / Total Stockholder Equity 245.4m)
RoCE = -61.73% (EBIT -170.3m / Capital Employed (Equity 245.4m + L.T.Debt 30.4m))
RoIC = -48.79% (negative operating profit) (NOPAT -134.5m / Invested Capital 275.7m)
WACC = 7.87% (E(95.2m)/V(155.1m) * Re(10.51%) + D(59.9m)/V(155.1m) * Rd(4.65%) * (1-Tc(0.21)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.25%
Fair Price DCF = unknown (Cash Flow -158.8m)
EPS Correlation: -3.08 | EPS CAGR: 15.78% | SUE: 1.25 | # QB: 1
Revenue Correlation: -42.46 | Revenue CAGR: -8.62% | SUE: 0.0 | # QB: 0

Additional Sources for PLRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle